Clinical Trial Update: Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tocilizumab for severe COVID-19 infection in breast cancer patients compared to non-cancer patients; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Beni-Suef University | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED